Exploiting bone niches: progression of disseminated tumor cells to metastasis
Aaron M. Muscarella, … , Sarah M. Waldvogel, Xiang H.-F. Zhang
Aaron M. Muscarella, … , Sarah M. Waldvogel, Xiang H.-F. Zhang
Published March 15, 2021
Citation Information: J Clin Invest. 2021;131(6):e143764. https://doi.org/10.1172/JCI143764.
View: Text | PDF
Review Series

Exploiting bone niches: progression of disseminated tumor cells to metastasis

Abstract

Many solid cancers metastasize to the bone and bone marrow (BM). This process may occur even before the diagnosis of primary tumors, as evidenced by the discovery of disseminated tumor cells (DTCs) in patients without occult malignancies. The cellular fates and metastatic progression of DTCs are determined by complicated interactions between cancer cells and BM niches. Not surprisingly, these niches also play important roles in normal biology, including homeostasis and turnover of skeletal and hematopoiesis systems. In this Review, we summarize recent findings on functions of BM niches in bone metastasis (BoMet), particularly during the early stage of colonization. In light of the rich knowledge of hematopoiesis and osteogenesis, we highlight how DTCs may progress into overt BoMet by taking advantage of niche cells and their activities in tissue turnover, especially those related to immunomodulation and bone repair.

Authors

Aaron M. Muscarella, Sergio Aguirre, Xiaoxin Hao, Sarah M. Waldvogel, Xiang H.-F. Zhang

×

Figure 1

Disseminated tumor cells utilize bone marrow niches to survive and colonize.

Options: View larger image (or click on image) Download as PowerPoint
Disseminated tumor cells utilize bone marrow niches to survive and colon...
Disseminated tumor cells (DTCs) occupy many niches in the bone after they arrive in the organ via the bloodstream. When cells first extravasate from the vessels, they may reside in the perivascular niche. DTCs occupy and compete with the HSC niche through recruitment by CXCR4/CXCL12 signaling to the perivascular niche. Several signaling pathways and molecules govern the dormancy/proliferation fate of cancer cells in this niche, including pericyte-derived thrombospondin-1 (TSP1). Cancer cells can also interact with cells of the osteoblast lineage, namely mesenchymal stem cells, preosteoblasts, and osteoblasts, which constitute the osteogenic niche. Here they use heterotypic cellular junctions as well as Jagged-1–mediated Notch signaling to crosstalk with the niche. Gap junctions formed between the cancer cells and osteogenic cells facilitate calcium transfer into the cancer cells. These interactions collectively promote DTC proliferation and chemoresistance. Osteoclastogenesis may be activated by multiple mechanisms, which leads to a feed-forward loop known as the vicious cycle. In this cycle, tumor cells produce both pro-osteoblastic and pro-osteolytic factors, stimulating both osteoblasts and osteoclast activity. The destruction of the bone releases embedded growth factors that act on tumor cells, further stimulating their growth. HSC, hematopoietic stem cell; LOX, lysyl oxidase; MSC, mesenchymal stem cell; PTHrP, parathyroid hormone–related protein.